김은규
#유방암의 외과적치료
|
학력
1999 서울대학교 의과대학 학사
2007 서울대학교 의과대학 외과학 석사
2011 서울대학교 의과대학 외과학 박사
2007 서울대학교 의과대학 외과학 석사
2011 서울대학교 의과대학 외과학 박사
경력
1999~2004 서울대학교병원 수련의 및 외과 전공의
2004~2007 육군 군의관 (36보병사단 의무대 치료반장, 청와대 의무실 외과 과장)
2007~2009 서울대학교병원 외과/유방센터 임상강사
2009~2014 한국원자력의학원 원자력병원 외과 10과장
2014~현재 분당서울대학교병원 외과 부교수
2017~2018 미국 하버드 의과대학 메사추세츠종합병원 연수
2004~2007 육군 군의관 (36보병사단 의무대 치료반장, 청와대 의무실 외과 과장)
2007~2009 서울대학교병원 외과/유방센터 임상강사
2009~2014 한국원자력의학원 원자력병원 외과 10과장
2014~현재 분당서울대학교병원 외과 부교수
2017~2018 미국 하버드 의과대학 메사추세츠종합병원 연수
논문
Kim EK, Hong SE, Jin HO, Kim HA, Lee JK, Koh JS, Seol H, Kim JI, Park IC, Noh WC. S6K1 inhibition enhances tamoxifen-induced cell death in MCF-7 cells through translational inhibition of Mcl-1 and survivin. Cell Biol Toxicol. 2013 Aug;29(4):273-82.
Kim EK, Kim JH, Kim HA, Seol H, Seong MK, Lee JY, Byeon J, Sohn YJ, Koh JS, Park IC, Noh WC. Phosphorylated S6 kinase-1: a breast cancer marker predicting resistance to neoadjuvant chemotherapy. Anticancer Res. 2013 Sept;33(9):4073-9.
Kim EK, Kim HA, Koh JS, Kim MS, Lee JI, Moon NM, Ko E, Noh WC. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2011 Feb;126(1):93-9.
Kim EK, Noh WC, Han W, Noh DY. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg. 2011 Jun;35(6):1244-53.
Kim EK, Kim RG, Kim HA, Koh JS, Kim MS, Kim KI, Lee JI, Moon NM, Ko E, Noh WC. Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience. Eur J Surg Oncol. 2011 Jul;37(7):629-34.
Kim EK, Kim KS, Park SK, Ahn SH, Lee MH, Kim SW, Korean Breast Cancer Society. The Korean Hereditary Breast Cancer (KOHBRA) study: protocol review. J Breast Cancer 2007 Dec 10(04): 241-247.
Jin HO, Lee YH, Park JA, Lee HN, Kim JH, Kim JY, Kim B, Hong SE, Kim HA, Kim EK, Noh WC, Kim JI, Chang YH, Hong SI, Hong YJ, Park IC, Lee JK. Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells. J Cancer Res Clin Oncol. 2014 Jul 15.
Yu JH, Lee JW, Son BH, Kim SW, Park SK, Lee MH, Kim LS, Noh WC, Kim EK, Yoon DS, Lee J, Jung JH, Jung SS, Gong G, Ahn SH. Characteristics of BRCA1/2 mutation-positive breast cancer in Korea: A comparison study based on multicenter data and the Korean breast cancer registry. J Breast Cancer. 2014 Jun;17(2):129-35.
Lim I, Noh WC, Park J, Park JA, Kim HA, Kim EK, Park KW, Lee SS, You EY, Kim KM, Byun BH, Kim BI, Choi CW, Lim SM. The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014 Jun 14. [Epub ahead of print].
Kim HS, Koh JS, Choi YB, Ro J, Kim HK, Kim MK, Nam BH, Kim KT, Chandra V, Seol HS, Noh WC, Kim EK, Park J, Bae CD, Hong KM. Chromatin CKAP2, an new proliferation markers, as independent prognostic indicator in breast cancer. PLoS One. 2014 Jun 2;9(6):e98160.
Kim HA, Lee JK, Kim EK, Seol H, Noh WC. Serum human epidermal growth factor receptor 2 levels as a real-time marker for tumor burden in breast cancer patients. J Surg Oncol. 2014 Apr;109(5):421-5.
Park J, Byun BH, Noh WC, Lee SS, Kim HA, Kim EK, Choi CW, Lim SM. Lymph node to primary tumor SUV ratio by 18F-FDG PET/CT and the prediction of axillary lymph node metastases in breast cancer. Clin Nucl Med. 2014 Apr;39(4):e249-53.
Kim J, Lim W, Kim EK, Kim MK, Paik NS, Jeong SS, Yoon JH, Park CH, Ahn SH, Kim LS, Han S, Nam SJ, Kang HS, Kim SI, Yoo YB, Jeong J, Kim TH, Kang T, Kim SW, Jung Y, Lee JE, Kim KS, Yu JH, Chae BJ, Jung SY, Kang E, Choi SY, Moon HG, Noh DY, Han W. Phase II randomized trial of neoadjuvant metrofmin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). BMC Cancer. 2014 Mar 10;14:170.
Ha JH, Seong MK, Kim EK, Lee JK, Seol H, Lee JY, Byeon J, Sohn YJ, Koh JS, Park IC, Noh WC, Kim HA. Serial serum HER2 measure measurements for the detection of breast cancer recurrence in HER2-positive patients. J Breast Cancer. 2014 Mar;17(1):33-9.
Park J, Byun BH, Noh WC, Lee SS, Kim HA, Kim EK, Choi CW, Lim SM. Lymph Node to Primary Tumor SUV Ratio by 18F-FDG PET/CT and the Prediction of Axillary Lymph Node Metastases in Breast Cancer. Clin Nucl Med. 2014 Apr;39(4):e249-53.
Jin HO, Lee YH, Park JA, Jim JH, Hong SE, Kim HA, Kim EK, Noh WC, Kim BH, Ye SK, Chang YH, Hong SI, Hong YJ, Park IC, Lee JK. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition. Biochem Biophys Res Commun. 2014 Feb 21;444(4):502-8.
Kim HA, Kim EK, Kim MS, Yu JH, Lee MR, Lee HK, Suh YJ, Noh WC; Korean Breast Cancer Society. Association of Human Epidermal Growth Factor Receptor 2 with Radiotherapy Resistance in Patients with T1N0M0 Breast Cancer. J Breast Cancer. 2013 Sep;16(3):266-73.
Lee J, Cho HJ, Yoo HW, Park SK, Yang JJ, Kim SW, Kang E, Ahn SH, Lee SJ, Suh YJ, Kim SY, Kim EK, Moon NM, Lee MH; Korean Hereditary Breast Cancer Research Group, Korean Breast Cancer Society. The effects of a genetic counseling educational program on hereditary breast cancer for Korean healthcare providers. J Breast Cancer. 2013 Sep;16(3):355-41.
Min JW, Kim KI, Kim HA, Kim EK, Noh WC, Jeon HB, Cho DH, Oh JS, Park IC, Hwang SG, Kim JS. INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells. Biochem Biophys Res Commun. 2013 Oct 11;440(1):137-42.
Byun BH, Noh WC, Lim I, Lee SS, Cho AR, Park JA, Kim KM, Kim HA, Kim EK, Kim BI, Choi CW, Lim SM. A new method for apparent diffusion coefficient measurement using sequential (18)F-FDG PET and MRI: correlation with histological grade of invasive ductal carcinoma of the breast. Ann Nucl Med. 2013 Oct;27(8):720-8.
Jin HO, Lee YH, Kim HA, Kim EK, Noh WC, Kim YS, Hwang CS, Kim JI, Chang YH, Hong SI, Hong YJ, Park IC, Lee JK. Inhibition of vacuolar H+ ATPase enhances sensitivity to tamoxifen via up-regulation of CHOP in breast cancer cells. Biochem Biophys Res Commun. 2013 Aug 2;437(3):463-8.
Jin HO, Hong SE, Kim JH, Choi HN, Kim K, An S, Choe TB, Hwang CS, Lee JH, Kim JI, Kim HA, Kim EK, Noh WC, Hong YJ, Hong SI, Lee JK, Park IC. Sustained overexpression of Redd1 leads to Akt activation involved in cell survival. Cancer Lett. 2013 Aug 19;336(2):319-24.
Choi HN, Jin HO, Kim JH, Hong SE, Kim HA, Kim EK, Lee JK, Park IC, Noh WC. Inhibition of S6K1 enhances glucose deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 2013 Mar 1;432(1):123-8.
Jin HO, Hong SE, Woo SH, Lee JH, Choe TB, Kim EK, Noh WC, Lee JK, Hong SI, Kim JI, Park IC. Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition. Cell Death Dis. 2012 Jun 7;3:e319.
Jin HO, Seo SK, Woo SH, Kim YS, Hong SE, Yi JY, Noh WC, Kim EK, Lee JK, Hong SI, Choe TB, Park IC. Redd1 inhibits the invasiveness of non-small cell lung cancer cells. Biochem Biophys Res Commun. 2011 Apr 15;407(3):507-11.
Lee JY, Kim HA, Kim EK, Yang HM, Kim KI, Lee JI, Koh JS, Ko EY, Moon NM, Kim MS, Paik NS, Noh WC. Different prognostic significance of Bcl-2 based on cancer molecular subtype. J Breast Cancer. 2011 Feb 14(Supple 1):S10-S16.
Lee J, Kang E, Kim SW, Park B, Park SK, Ahn SH, Lee HD, Jeong J, Jung SH, Lee BK, Chang MC, Bae YT, Cho YU, Hwang KT, Kim HA, Kim EK, Paik NS, Han S, Yoon CS, Lee MH, Korean Breast Cancer Society. The prevalence of ovarian cancer in Korean women at high-risk for hereditary breast-ovarian cancer. J Breast Cancer. 2011 Feb 14(Supple 1):S24-S30.
Chung IY, Kang E, Yang EJ, Lim JY, Kim EK, Kim HA, Noh WC, Kim JI, Park MH, Yoon JH, Lee JE, Nam SJ, Yang JH, Lee BK, Jung SH, Youn HJ, Kim KS, Jung SY, Moon BI, Kim SW. Survey of psychosocial problems facing breast cancer survivors after undergoing a mastectomy and their awareness of breast reconstruction. J Breast Cancer. 2011 Feb 14(Supple 1): S70-S76.
Ko E, Han W, Cho J, Lee JW, Kang SY, Jung SY, Kim EK, Hwang KT, Noh DY. Fibrin glue reduces the duration of lymphatic drainage after lumpectomy and level II or III axillary lymph node dissection for breast cancer: a prospective randomized trial. J Korean Med Sci. 2009 Feb;24(1):92-6.
Jung SY, Han W, Lee JW, Ko E, Kim EK, Yu JH, Moon HG, Park IA, Oh DY, Im SA, Kim TY, Hwang KT, Kim SW, Noh DY. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol. 2009 May;16(5):1112-21.
Moon HG, Han W, Lee JW, Ko E, Kim EK, Yu JH, Kang SY, Moon WK, Cho N, Park IA, Oh DY, Han SW, Im SA, Noh DY. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol. 2009 Apr;20(4):636-41.
Hwang KT, Han W, Cho J, Lee JW, Ko E, Kim EK, Jung SY, Jeong EM, Bae JY, Kang JJ, Yang SJ, Kim SW, Noh DY. Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. Int J Cancer. 2008 Oct 15;123(8):1807-15.
Cho J, Han W, Lee JW, Ko E, Kang SY, Jung SY, Kim EK, Moon WK, Cho N, Park IA, Chung JK, Hwang KT, Kim SW, Noh DY. A scoring system to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a comparison with other scoring systems. Ann Surg Oncol. 2008 Aug;15(8):2278-86.
Lee JW, Han W, Ko E, Cho J, Kim EK, Jung SY, Cho N, Moon WK, Park IA, Noh DY. Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus. J Surg Oncol. 2008 Jul 1;98(1):15-20.
Ko E, Han W, Lee JW, Cho J, Kim EK, Jung SY, Kang MJ, Moon WK, Park IA, Kim SW, Kim KS, Lee ES, Min KH, Kim SW, Noh DY. Scoring system for predicting malignancy in patients diagnosed with atypical ductal hyperplasia at ultrasound-guided core needle biopsy. Breast Cancer Res Treat. 2008 Nov;112(1):189-95.
Kim JH, Han W, Moon HG, Ko E, Lee JW, Kim EK, Park IA, Ha SW, Chie EK, Oh SK, Youn YK, Kim SW, Hwang KT, Noh DY. Factors affecting the ipsilateral breast tumor recurrence after breast conserving therapy in patients with T1 and T2 tumors. J Breast Cancer 2009 Dec 12(04): 324-330.
Ha HK, Han W, Ko E, Kang SY, Lee JW, Cho J, Jung SY, Kim EK, Oh SK, Youn YK, Noh DY. Toremifene as an adjuvant hormone therapy for estrogen receptor positive early breast cancer: therapeutic efficacy and effect on endometrium. J Breast Cancer 2007 Dec 10(04): 258-262.
Lee JW, Han W, Ko E, Cho J, Jung SY, Kim EK, Keam BS, Im SA, Lee HC, Park IA, Oh SK, Youn YK, Kim SW, Hwang KT, Noh DY. Alteration of estrogen receptor, progesterone receptor, and HER-2 expression in breast cancer after neoadjuvant chemotherapy. J Breast Cancer 2007 Sep 10(03): 206-210.
Cho J, Han W, Ko E, Lee JW, Jung SY, Kim EK, Lee HC, Park IA, Oh SK, Youn YK, Kim SW, Hwang KT, Noh DY. The clinical and histopathological characteristics of male breast cancer patients. J Breast Cancer 2007 Sep 10(03): 211-216.
Kim EK, Kim JH, Kim HA, Seol H, Seong MK, Lee JY, Byeon J, Sohn YJ, Koh JS, Park IC, Noh WC. Phosphorylated S6 kinase-1: a breast cancer marker predicting resistance to neoadjuvant chemotherapy. Anticancer Res. 2013 Sept;33(9):4073-9.
Kim EK, Kim HA, Koh JS, Kim MS, Lee JI, Moon NM, Ko E, Noh WC. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2011 Feb;126(1):93-9.
Kim EK, Noh WC, Han W, Noh DY. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study. World J Surg. 2011 Jun;35(6):1244-53.
Kim EK, Kim RG, Kim HA, Koh JS, Kim MS, Kim KI, Lee JI, Moon NM, Ko E, Noh WC. Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience. Eur J Surg Oncol. 2011 Jul;37(7):629-34.
Kim EK, Kim KS, Park SK, Ahn SH, Lee MH, Kim SW, Korean Breast Cancer Society. The Korean Hereditary Breast Cancer (KOHBRA) study: protocol review. J Breast Cancer 2007 Dec 10(04): 241-247.
Jin HO, Lee YH, Park JA, Lee HN, Kim JH, Kim JY, Kim B, Hong SE, Kim HA, Kim EK, Noh WC, Kim JI, Chang YH, Hong SI, Hong YJ, Park IC, Lee JK. Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells. J Cancer Res Clin Oncol. 2014 Jul 15.
Yu JH, Lee JW, Son BH, Kim SW, Park SK, Lee MH, Kim LS, Noh WC, Kim EK, Yoon DS, Lee J, Jung JH, Jung SS, Gong G, Ahn SH. Characteristics of BRCA1/2 mutation-positive breast cancer in Korea: A comparison study based on multicenter data and the Korean breast cancer registry. J Breast Cancer. 2014 Jun;17(2):129-35.
Lim I, Noh WC, Park J, Park JA, Kim HA, Kim EK, Park KW, Lee SS, You EY, Kim KM, Byun BH, Kim BI, Choi CW, Lim SM. The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014 Jun 14. [Epub ahead of print].
Kim HS, Koh JS, Choi YB, Ro J, Kim HK, Kim MK, Nam BH, Kim KT, Chandra V, Seol HS, Noh WC, Kim EK, Park J, Bae CD, Hong KM. Chromatin CKAP2, an new proliferation markers, as independent prognostic indicator in breast cancer. PLoS One. 2014 Jun 2;9(6):e98160.
Kim HA, Lee JK, Kim EK, Seol H, Noh WC. Serum human epidermal growth factor receptor 2 levels as a real-time marker for tumor burden in breast cancer patients. J Surg Oncol. 2014 Apr;109(5):421-5.
Park J, Byun BH, Noh WC, Lee SS, Kim HA, Kim EK, Choi CW, Lim SM. Lymph node to primary tumor SUV ratio by 18F-FDG PET/CT and the prediction of axillary lymph node metastases in breast cancer. Clin Nucl Med. 2014 Apr;39(4):e249-53.
Kim J, Lim W, Kim EK, Kim MK, Paik NS, Jeong SS, Yoon JH, Park CH, Ahn SH, Kim LS, Han S, Nam SJ, Kang HS, Kim SI, Yoo YB, Jeong J, Kim TH, Kang T, Kim SW, Jung Y, Lee JE, Kim KS, Yu JH, Chae BJ, Jung SY, Kang E, Choi SY, Moon HG, Noh DY, Han W. Phase II randomized trial of neoadjuvant metrofmin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). BMC Cancer. 2014 Mar 10;14:170.
Ha JH, Seong MK, Kim EK, Lee JK, Seol H, Lee JY, Byeon J, Sohn YJ, Koh JS, Park IC, Noh WC, Kim HA. Serial serum HER2 measure measurements for the detection of breast cancer recurrence in HER2-positive patients. J Breast Cancer. 2014 Mar;17(1):33-9.
Park J, Byun BH, Noh WC, Lee SS, Kim HA, Kim EK, Choi CW, Lim SM. Lymph Node to Primary Tumor SUV Ratio by 18F-FDG PET/CT and the Prediction of Axillary Lymph Node Metastases in Breast Cancer. Clin Nucl Med. 2014 Apr;39(4):e249-53.
Jin HO, Lee YH, Park JA, Jim JH, Hong SE, Kim HA, Kim EK, Noh WC, Kim BH, Ye SK, Chang YH, Hong SI, Hong YJ, Park IC, Lee JK. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition. Biochem Biophys Res Commun. 2014 Feb 21;444(4):502-8.
Kim HA, Kim EK, Kim MS, Yu JH, Lee MR, Lee HK, Suh YJ, Noh WC; Korean Breast Cancer Society. Association of Human Epidermal Growth Factor Receptor 2 with Radiotherapy Resistance in Patients with T1N0M0 Breast Cancer. J Breast Cancer. 2013 Sep;16(3):266-73.
Lee J, Cho HJ, Yoo HW, Park SK, Yang JJ, Kim SW, Kang E, Ahn SH, Lee SJ, Suh YJ, Kim SY, Kim EK, Moon NM, Lee MH; Korean Hereditary Breast Cancer Research Group, Korean Breast Cancer Society. The effects of a genetic counseling educational program on hereditary breast cancer for Korean healthcare providers. J Breast Cancer. 2013 Sep;16(3):355-41.
Min JW, Kim KI, Kim HA, Kim EK, Noh WC, Jeon HB, Cho DH, Oh JS, Park IC, Hwang SG, Kim JS. INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells. Biochem Biophys Res Commun. 2013 Oct 11;440(1):137-42.
Byun BH, Noh WC, Lim I, Lee SS, Cho AR, Park JA, Kim KM, Kim HA, Kim EK, Kim BI, Choi CW, Lim SM. A new method for apparent diffusion coefficient measurement using sequential (18)F-FDG PET and MRI: correlation with histological grade of invasive ductal carcinoma of the breast. Ann Nucl Med. 2013 Oct;27(8):720-8.
Jin HO, Lee YH, Kim HA, Kim EK, Noh WC, Kim YS, Hwang CS, Kim JI, Chang YH, Hong SI, Hong YJ, Park IC, Lee JK. Inhibition of vacuolar H+ ATPase enhances sensitivity to tamoxifen via up-regulation of CHOP in breast cancer cells. Biochem Biophys Res Commun. 2013 Aug 2;437(3):463-8.
Jin HO, Hong SE, Kim JH, Choi HN, Kim K, An S, Choe TB, Hwang CS, Lee JH, Kim JI, Kim HA, Kim EK, Noh WC, Hong YJ, Hong SI, Lee JK, Park IC. Sustained overexpression of Redd1 leads to Akt activation involved in cell survival. Cancer Lett. 2013 Aug 19;336(2):319-24.
Choi HN, Jin HO, Kim JH, Hong SE, Kim HA, Kim EK, Lee JK, Park IC, Noh WC. Inhibition of S6K1 enhances glucose deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 2013 Mar 1;432(1):123-8.
Jin HO, Hong SE, Woo SH, Lee JH, Choe TB, Kim EK, Noh WC, Lee JK, Hong SI, Kim JI, Park IC. Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition. Cell Death Dis. 2012 Jun 7;3:e319.
Jin HO, Seo SK, Woo SH, Kim YS, Hong SE, Yi JY, Noh WC, Kim EK, Lee JK, Hong SI, Choe TB, Park IC. Redd1 inhibits the invasiveness of non-small cell lung cancer cells. Biochem Biophys Res Commun. 2011 Apr 15;407(3):507-11.
Lee JY, Kim HA, Kim EK, Yang HM, Kim KI, Lee JI, Koh JS, Ko EY, Moon NM, Kim MS, Paik NS, Noh WC. Different prognostic significance of Bcl-2 based on cancer molecular subtype. J Breast Cancer. 2011 Feb 14(Supple 1):S10-S16.
Lee J, Kang E, Kim SW, Park B, Park SK, Ahn SH, Lee HD, Jeong J, Jung SH, Lee BK, Chang MC, Bae YT, Cho YU, Hwang KT, Kim HA, Kim EK, Paik NS, Han S, Yoon CS, Lee MH, Korean Breast Cancer Society. The prevalence of ovarian cancer in Korean women at high-risk for hereditary breast-ovarian cancer. J Breast Cancer. 2011 Feb 14(Supple 1):S24-S30.
Chung IY, Kang E, Yang EJ, Lim JY, Kim EK, Kim HA, Noh WC, Kim JI, Park MH, Yoon JH, Lee JE, Nam SJ, Yang JH, Lee BK, Jung SH, Youn HJ, Kim KS, Jung SY, Moon BI, Kim SW. Survey of psychosocial problems facing breast cancer survivors after undergoing a mastectomy and their awareness of breast reconstruction. J Breast Cancer. 2011 Feb 14(Supple 1): S70-S76.
Ko E, Han W, Cho J, Lee JW, Kang SY, Jung SY, Kim EK, Hwang KT, Noh DY. Fibrin glue reduces the duration of lymphatic drainage after lumpectomy and level II or III axillary lymph node dissection for breast cancer: a prospective randomized trial. J Korean Med Sci. 2009 Feb;24(1):92-6.
Jung SY, Han W, Lee JW, Ko E, Kim EK, Yu JH, Moon HG, Park IA, Oh DY, Im SA, Kim TY, Hwang KT, Kim SW, Noh DY. Ki-67 expression gives additional prognostic information on St. Gallen 2007 and Adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol. 2009 May;16(5):1112-21.
Moon HG, Han W, Lee JW, Ko E, Kim EK, Yu JH, Kang SY, Moon WK, Cho N, Park IA, Oh DY, Han SW, Im SA, Noh DY. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol. 2009 Apr;20(4):636-41.
Hwang KT, Han W, Cho J, Lee JW, Ko E, Kim EK, Jung SY, Jeong EM, Bae JY, Kang JJ, Yang SJ, Kim SW, Noh DY. Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. Int J Cancer. 2008 Oct 15;123(8):1807-15.
Cho J, Han W, Lee JW, Ko E, Kang SY, Jung SY, Kim EK, Moon WK, Cho N, Park IA, Chung JK, Hwang KT, Kim SW, Noh DY. A scoring system to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a comparison with other scoring systems. Ann Surg Oncol. 2008 Aug;15(8):2278-86.
Lee JW, Han W, Ko E, Cho J, Kim EK, Jung SY, Cho N, Moon WK, Park IA, Noh DY. Sonographic lesion size of ductal carcinoma in situ as a preoperative predictor for the presence of an invasive focus. J Surg Oncol. 2008 Jul 1;98(1):15-20.
Ko E, Han W, Lee JW, Cho J, Kim EK, Jung SY, Kang MJ, Moon WK, Park IA, Kim SW, Kim KS, Lee ES, Min KH, Kim SW, Noh DY. Scoring system for predicting malignancy in patients diagnosed with atypical ductal hyperplasia at ultrasound-guided core needle biopsy. Breast Cancer Res Treat. 2008 Nov;112(1):189-95.
Kim JH, Han W, Moon HG, Ko E, Lee JW, Kim EK, Park IA, Ha SW, Chie EK, Oh SK, Youn YK, Kim SW, Hwang KT, Noh DY. Factors affecting the ipsilateral breast tumor recurrence after breast conserving therapy in patients with T1 and T2 tumors. J Breast Cancer 2009 Dec 12(04): 324-330.
Ha HK, Han W, Ko E, Kang SY, Lee JW, Cho J, Jung SY, Kim EK, Oh SK, Youn YK, Noh DY. Toremifene as an adjuvant hormone therapy for estrogen receptor positive early breast cancer: therapeutic efficacy and effect on endometrium. J Breast Cancer 2007 Dec 10(04): 258-262.
Lee JW, Han W, Ko E, Cho J, Jung SY, Kim EK, Keam BS, Im SA, Lee HC, Park IA, Oh SK, Youn YK, Kim SW, Hwang KT, Noh DY. Alteration of estrogen receptor, progesterone receptor, and HER-2 expression in breast cancer after neoadjuvant chemotherapy. J Breast Cancer 2007 Sep 10(03): 206-210.
Cho J, Han W, Ko E, Lee JW, Jung SY, Kim EK, Lee HC, Park IA, Oh SK, Youn YK, Kim SW, Hwang KT, Noh DY. The clinical and histopathological characteristics of male breast cancer patients. J Breast Cancer 2007 Sep 10(03): 211-216.
저서
유전성 유방암 (군자출판사, 2012)
보도자료
유방암 전절제술 때 가슴 외형 보존 가능
https://news.naver.com/main/read.nhn?mode=LSD&mid=sec&sid1=103&oid=032&aid=0002992391
한국 여성암 1위 '유방암', 젊은 유방암 환자 수가 늘고 있다? - 외과 김은규 교수
https://blog.naver.com/happy_snubh/221671898314
[명의에게 묻다] "유방암, 이제 '절망의 질환' 아닙니다"
https://news.naver.com/main/read.nhn?mode=LSD&mid=sec&sid1=102&oid=001&aid=0010916077
https://news.naver.com/main/read.nhn?mode=LSD&mid=sec&sid1=103&oid=032&aid=0002992391
한국 여성암 1위 '유방암', 젊은 유방암 환자 수가 늘고 있다? - 외과 김은규 교수
https://blog.naver.com/happy_snubh/221671898314
[명의에게 묻다] "유방암, 이제 '절망의 질환' 아닙니다"
https://news.naver.com/main/read.nhn?mode=LSD&mid=sec&sid1=102&oid=001&aid=0010916077
포스팅
포스팅 내용이 없습니다.
영상자료
영상자료 내용이 없습니다.
발표자료
발표자료 내용이 없습니다.